Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.68 |
| ▸ | JAK1 | P23458 | 8/20 | 0.64 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.58 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15655892 | 0.84 | EGLN2 (0.60) | EGLN2JAK1NUDT1JAK3JAK2 | |
| SCHEMBL3210558 | 0.81 | EGLN2 (1.00) | EGLN2JAK1NUDT1JAK3JAK2 | |
| SCHEMBL2185451 | 0.80 | JAK1 (0.65) | EGLN2JAK1NUDT1JAK3JAK2 | |
| SCHEMBL3090231 | 0.79 | JAK1 (1.00) | EGLN2JAK1NUDT1JAK3JAK2 | |
| SCHEMBL15654688 | 0.78 | NUDT1 (0.66) | EGLN2JAK1NUDT1JAK3JAK2 | |
| SCHEMBL15655236 | 0.78 | EGLN2 (0.68) | EGLN2JAK1NUDT1JAK3JAK2 | |
| SCHEMBL3601961 | 0.76 | NUDT1 (0.78) | EGLN2JAK1NUDT1JAK3JAK2 | |
| SCHEMBL7989292 | 0.76 | JAK2 (0.60) | EGLN2JAK1JAK3JAK2TYK2 | |
| SCHEMBL3262251 | 0.76 | NUDT1 (0.71) | EGLN2JAK1NUDT1JAK3JAK2 | |
| SCHEMBL15654781 | 0.75 | JAK2 (0.63) | EGLN2JAK1NUDT1JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2017-02-09 | — | — | US | disclosed |
| US-9415037-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-08-16 | — | — | US | disclosed |
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | EGLN2 1133/4885JAK1 100/4885NUDT1 2558/4885 |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | TRAF6, TLR6, IL6 | EGLN2 824/4885JAK1 115/4885NUDT1 2363/4885 |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | EGLN2 1133/4885JAK1 100/4885NUDT1 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.